D35E148D-0537-4186-8B19-17915782AF18
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 33.70565045992115
- age_years
- 32
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.392
- MYC_TARGETS_V1+0.385
- G2M_CHECKPOINT+0.377
- NOTCH_SIGNALING+0.374
- MYC_TARGETS_V2+0.341
- MITOTIC_SPINDLE+0.338
- UNFOLDED_PROTEIN_RESPONSE+0.321
- DNA_REPAIR+0.317
- WNT_BETA_CATENIN_SIGNALING+0.314
- TGF_BETA_SIGNALING+0.285
Top 10 suppressed
- COAGULATION-0.366
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.352
- ANGIOGENESIS-0.341
- KRAS_SIGNALING_DN-0.324
- ALLOGRAFT_REJECTION-0.315
- COMPLEMENT-0.306
- MYOGENESIS-0.303
- INFLAMMATORY_RESPONSE-0.281
- TNFA_SIGNALING_VIA_NFKB-0.275
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.239
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 10FB7E59-9D71-4AB9-8D06-9CFD2304D1BC | — | — | 0.952 |
| 2 | 713B4DA5-FA8A-4E52-BACF-19B912467FBB | — | — | 0.949 |
| 3 | 2C70D7BF-85C4-447B-B0F9-A129D6B49E77 | — | — | 0.945 |
| 4 | B8B72B5C-536A-40E3-9E7F-95E7629874D3 | — | — | 0.941 |
| 5 | SRR934777 | — | — | 0.941 |
| 6 | DB57CFA5-B8EA-4A08-B6CC-EF55C0E213D4 | — | — | 0.937 |
| 7 | A770E81F-8898-4632-A839-7950EED7CF7A | — | — | 0.934 |
| 8 | 46BEFC7F-2F51-4331-BA86-9823EC5781B3 | — | — | 0.934 |
| 9 | CA9E9B92-5D16-4455-ACC8-ACBFDFB754C5 | — | — | 0.933 |
| 10 | 2DA298A9-AB20-4F9D-B83F-C7FC0679F889 | — | — | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.392 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.385 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.377 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.374 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.341 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.338 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.321 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.317 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.314 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.285 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.257 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.229 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.191 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.123 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.056 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.042 | Temsirolimus | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.005 | Inavolisib | — uncovered |